Recognition that myocardial infarction is caused by coronary thrombosis has stimulated a search for a safe, rapidly acting, and effective thrombolytic regimen. Tissue plasminogen activator (t-PA) can provide relatively clot-selective thrombolysis, but one quarter of patients fail to achieve reperfusion, lysis speed is not optimal, and higher doses have been associated with an increased incidenc...

Several tumor cells secrete significantly increased amounts of the plasminogen activator urokinase, a trypsinlike serine protease, whose biological function in tumor biology is unclear. In this study we report that cells of the human epidermal tumor cell line CCL 20.2 express about 80,000 high-affinity urokinase receptors per cell that bind active as well as diisopropylfluorophosphate-treated h...

Plasma fibrinolytic activity and plasma inhibitory activity against urokinase and tissue activator were measured in primigravidae with moderate or severe pre-eclampsia and in gestation-matched primigravidae with uncomplicated pregnancy. The mean levels of fibrinolytic activity and inhibitory activity against urokinase and tissue activator did not differ significantly between the pre-eclampsia a...

BACKGROUND Although plasminogen activator therapy has been shown to reduce mortality in patients with severe myocardial infarction, several problems fuel the search for more potent and specific thrombolytic agents. METHODS AND RESULTS To explore the effect of plasminogen activator targeting to platelets, we covalently linked urokinase that had been modified with N-succinimidyl-3-(2-pyridyldit...

PURPOSE To examine the effect of several agents that either stimulate or inhibit neovascularization on plasminogen activator inhibitor-1 and urokinase in retinal pigmented epithelial cells and vascular endothelial cells. METHODS Steady-state levels of messenger RNA were assessed by Northern blots and dot blots and protein levels were assessed by immunoprecipitation. RESULTS Data indicate th...

An occlusive thrombus was produced by thrombin-induced coagulation in the left anterior descending coronary artery of 18 open chest baboons. In six control animals, occlusive thrombosis persisting for 4 hours resulted in a large transmural infarct (66 +/- 4% of the perfusion area, mean +/- SEM). In six animals, single chain urokinase-type plasminogen activator, obtained by recombinant deoxyribo...

Serum soluble urokinase-type plasminogen activator receptor (suPAR) is a glycoprotein secreted during infections and inflammation . Urokinase-type plasminogen activator (uPA) is secreted by polymorphonuclear neutrophils (PMN) and macrophages; then uPA binds to membrane urokinase-type plasminogen activator receptor (uPAR) . suPAR is formed by cleaved from the uPAR . suPAR is expressed in various...

A vascular plasminogen activator obtained by perfusion of the vessels of the lower extremities of human cadavers has been purified to apparent homogeneity by sequential precipitation in ammonium sulfate, reverse ammonium sulfate gradient solubilization, hydrophobic chromatography on octyl-Sepharose, and gel filtration on Sephadex G-75 and G-150. The isolation procedures were carried out in the ...

IED20006 THE FIRST clinical report of the use of a thrombolytic agent (streptokinase) to treat acute pulmonary embolism (PE) appeared in 1964,1 and the first randomized clinical trial comparing urokinase plus heparin with heparin alone was published in 1970.2 A randomized clinical trial comparing urokinase to streptokinase in the treatment of PE was published in 1974.3 The first report of a thi...